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Virological residual activity (VRA) denotes the degree of HIV RNA suppression achieved by antiretroviral therapy
in the presence of resistant virus. This concept is particularly important in resource-limited settings, where rapid
switching after detection of virological failure may not be feasible. Using data from the NORA trial, we estimated
VRA for two regimens—zidovudine-lamivudine-abacavir (ZDV-3TC-ABC) and zidovudine-lamivudine-nevirapine
(ZDV-3TC-NVP)—and related this to the phenotypic drug sensitivity of the component drugs in the two regimens.
Plasma samples at weeks 0, 48, and 96 were retrospectively assayed for HIV-1 RNA, and genotypic/phenotypic
resistance testing was performed if HIV-1 RNA exceeded 1,000 copies/ml. Virological residual activity (VRA) was
defined as the difference between log10(HIV RNA) at week 48 or 96 and week 0 and related to 50% inhibitory
concentration (IC50) relative to wild-type virus for ZDV and ABC (fold change [FC]). Twenty-seven samples in the
ZDV-3TC-NVP group and 56 in the ZDV-3TC-ABC group contributed to the analysis. Mean VRA was significantly
higher in the ZDV-3TC-ABC group than in the ZDV-3TC-NVP at week 48 (1.62 versus 0.90) and week 96 (1.29
versus 0.78). There was a weak and nonsignificant relationship between VRA and ZDV FC, with VRA decreasing by
0.1 log10 copies/ml per 2-fold increase in ZDV. The association with ABC FC was much stronger, with a marked
reduction in VRA occurring at ABC FC values greater than approximately 2. This information should be considered
in future treatment guidelines relevant to resource-poor settings.
Rollout of HIV antiretroviral therapy (ART) in resource-
poor settings is characterized by two major differences to that
in resource-rich countries: first, few drug combinations are
available, and second, there is limited capacity for virological
monitoring (HIV RNA viral load, drug resistance testing) of
treatment (15). Consequently, patients may experience pro-
longed periods of undiagnosed viremia on therapy, which can
result in immunological compromise via depletion of CD4
count (20) and an increased risk of transmission (28). How-
ever, there are few data on the complex and dynamic relation-
ship between evolving drug resistance and the level of viremia
(25).
We refer to the degree of HIV RNA suppression achieved
by antiretroviral therapy in the presence of virus that is resis-
tant to one or more drugs in the regimen as “virological resid-
ual activity” (VRA). At least two factors are involved: a direct
antiviral effect of therapy and the maintenance of drug-asso-
ciated mutations that are detrimental to the fitness of the virus
in the absence of drug (10). VRA has been estimated mainly
from selective (partial) treatment interruption studies by ob-
serving the short-term increase in HIV RNA after discontin-
uation of one or more antiretroviral drugs while maintaining
the other drugs in the current regimen (4, 10, 12, 31). The
duration of follow-up in most of these studies has been too
short to observe the impact of the reversion of drug-associated
mutations on VRA.
Another approach is to compare HIV RNA level in a base-
line (pretherapy) sample with that in a later sample in which
high-level viral resistance is observed or assumed. Such ana-
lyses were performed in early studies of monotherapy and dual
therapy (2, 11, 13, 24, 27) but are generally no longer possible
because of the current practice of switching therapy in early
virological failure (17). An exception is studies in resource-
limited settings where access to concurrent HIV RNA testing
may not be available but where plasma samples can be stored
for retrospective analysis.
One such study is NORA, a randomized trial in Uganda that
compared abacavir (ABC) with nevirapine (NVP) in combina-
tion with zidovudine-lamivudine (ZDV-3TC). Nevirapine
demonstrated short-term virological and immunological supe-
riority over abacavir, although this was not reflected in clinical
outcomes (22). Here, we have estimated VRA for the two
regimens used in NORA and related it to the phenotypic drug
sensitivity of the component drugs.
(This study was presented in part at the 17th Conference on
Retroviruses and Opportunistic Infections, San Francisco, CA,
16 to 19 February 2010.)
MATERIALS AND METHODS
DART was a randomized trial in Uganda and Zimbabwe comparing clinically
driven monitoring versus laboratory (CD4/hematology/biochemistry) and clinical
monitoring in HIV-infected adults initiating ART with 200 CD4 cells/mm3 (9).
NORA was a randomized double-blind trial conducted in the two Ugandan
centers as a substudy within DART (8, 22, 23). Six hundred participants were
randomly allocated in a 1:1 ratio to receive zidovudine-lamivudine (ZDV-3TC)
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plus either 300 mg abacavir and nevirapine placebo or abacavir placebo and 200
mg nevirapine twice daily. Some participants in NORA were also randomized at
52/76 weeks to a substudy of structured treatment interruptions (repeated cycles
of 12 weeks off/on treatment or continuous therapy) (7).
Both the DART study and the NORA substudy received ethics approval in
Uganda (Uganda Research Unit on AIDS [UVRI] Science and Ethics Commit-
tee) and the United Kingdom (Imperial College). DART is registered as ISRC
TN13968779.
Laboratory measurements. All HIV-1 RNA measurements and resistance
tests were performed retrospectively, i.e., could not be used to guide therapy
management in real time (23). Stored plasma samples taken at baseline and 4, 12,
24, 48, and 96 weeks were assayed for HIV-1 RNA using a Roche Amplicor v1.5
assay for baseline samples (range of 400 to 750,000 copies/ml) or a Roche
ultrasensitive assay for other samples (range of 50 to 100,000 copies/ml). Samples
with HIV RNA above the linear dynamic range which met the inclusion criteria
for the current analysis (see below) were retested after 2- to 10-fold dilution to
achieve uncensored values. Genotypic (VircoTYPE 4.3.01) (29, 30) and pheno-
typic (Antivirogram 2.5.01, Virco BVBA) (16) resistance testing was performed
on samples with HIV-1 RNA of 1,000 copies/ml at 48/96 weeks and on the
corresponding baseline samples. For each drug, phenotypic resistance was ex-
pressed as the fold change (FC) in 50% inhibitory concentration (IC50) com-
pared to that of wild-type (HXB2) virus. Some FC values for lamivudine and
nevirapine, but not for zidovudine and abacavir, were right censored. Key mu-
tations were identified by reference to the 2009 IAS-USA classification (18).
Selection criteria. Selection criteria for the current analysis are shown in
Table 1. Of note are the following: (i) data at week 96 from patients who
underwent structured treatment interruptions (from week 52 or 76) were ex-
cluded, as this intervention is likely to have had a major influence on HIV RNA
levels and resistance patterns at week 96; (ii) data were excluded if the original
allocated treatment had been modified, as the aim was to estimate the VRA of
the regimens used in NORA; (iii) only those samples with HIV RNA of 1,000
copies/ml could be analyzed, since resistance testing was not attempted below
this level; (iv) data were excluded if no major resistance mutations were detected,
since this suggests that nonadherence was a likely cause of the viremia; and (v)
three outlying data points, which were found to have a strong influence on the
fitted regression models, were excluded (detailed in Table 2).
Statistical methods. Virological residual activity (VRA) was defined as the
difference between log10(HIV RNA) at week 48 or 96 and week 0, i.e.,
VRAwk 48/96  log10(HIV RNA)wk 0  log10(HIV RNA)wk 48/96. Multivariate
regression modeling was used to relate VRA to zidovudine FC using the ZDV-
3TC-NVP group and jointly to zidovudine FC and abacavir FC using the ZDV-
3TC-ABC group, adjusting for baseline HIV RNA. FC values were log trans-
formed before analysis. There was insufficient variability in lamivudine FC or
nevirapine FC (see Results) to examine the effects of these drugs. The mfp
command (STATA; StataCorp LP, College Station, TX) was used to find the
best-fitting fractional polynomial models (26). The addition of selected clinical
and immunological variables did not significantly improve the fit of the models.
Interaction tests provided no evidence that the relationship between VRA and
FC was different at 48 and 96 weeks, justifying the pooling of data across time
points. Standard errors were adjusted to account for the fact that some partici-
pants were observed at both time points.
RESULTS
Baseline characteristics in NORA have been described else-
where (8). In summary, 72% of the participants were female,
median age was 37 years, 18% had WHO stage 4 disease, and
median CD4 count was 99 cells/mm3, similar to the character-
istics of those included in this subanalysis. The rate of virolog-
ical failure was higher for ZDV-3TC-ABC than for ZDV-3TC-
NVP (22). A description of resistance findings and estimates of
VRA are presented separately for the two regimens. However,
the M184V mutation was ubiquitous in both groups and re-
sulted in high-level phenotypic resistance to lamivudine (me-
dian of 58 FC, range of 11 to 147 FC).
ZDV-3TC-NVP. Twenty-seven observations met the inclu-
sion criteria in the zidovudine-lamivudine-nevirapine (ZDV-
3TC-NVP) group (Table 1). Fifty-four percent (6/11) of the
samples had one or more thymidine analogue mutations
(TAMs) at 48 weeks (median of 2), compared with 88% (14/
16) of samples at 96 weeks (median of 4). All but one sample
had 1 major nonnucleoside reverse transcriptase inhibitor
(NNRTI) mutation, the most frequent individual mutations
being G190AS, K103N, and Y181C/I. Because of the uniformly
high level of phenotypic resistance to nevirapine in samples
with NNRTI mutations (median of 55 FC, range of 44 to
71 FC), the one sample lacking these mutations was excluded
from further analysis, and VRA was related to zidovudine FC
only (26 observations, 6 patients with observations at both 48
and 96 weeks). The median (interquartile range [IQR]) FCs
TABLE 1. Selection criteria
Parameter
No. of observationsg
ZDV-3TC-ABC ZDV-3TC-NVP
Wk 48 Wk 96 Wk 48 Wk 96
No. of patients randomized 300 300 300 300
Exclusion of data after STIi
randomization
300 263 300 229
No. of patients on original
regimena
245 186 220 154
HIV RNA result available at
baseline and at wk 48/96b
240 182 213 151
HIV RNA of 1,000 copies/ml 50 48 24 20
Phenotypic result availablec 35 32 14 16
1 major IAS mutationd 30 29 11 16
Exclusion of highly influential
observationse
29* 27* 11 16
1 major NNRTI mutationf NAh NA 10* 16*
a Most changes from the original regimen were due to substitution of zidovu-
dine with stavudine, abacavir with tenofovir, or nevirapine with tenofovir. Seven
patients started second-line therapy, based on lopinavir-ritonavir.
b Excluding 3 samples with undetectable HIV RNA at baseline.
c Mainly accounted for by insufficient sample material.
d Restriction applied to exclude virological failure likely due to nonadherence.
e Outlying observations which strongly influenced model fit (details in Ta-
ble 2).
f Restriction applied to allow simplification of statistical model.
g , samples included in the final model.
h NA, not applicable.
i STI, structured treatment interruption.
TABLE 2. Outlying observations on 3 patients
Baseline
HIV RNA HIV RNA (wk) VRA Major RT
a mutation(s) Phenotypic resistance (FC)
4.74 4.79 (96) 0.05 M184V ABC, 0.69; ZDV, 0.84
6.59 5.41 (96) 1.18 69insb, Y115F, M184V, L210W, T215F/Y ABC, 18.94; ZDV, 36.96
6.64 3.29 (48) 3.35 M184V ABC, 3.08; ZDV, 0.65
a RT, reverse transcriptase.
b 69ins, 69 insertion complex.
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for zidovudine were 0.7 (0.4, 0.9), 0.6 (0.4, 1.3), and 2.0 (0.8,
6.6) at weeks 0, 48, and 96, respectively.
Mean (standard deviation [SD]) HIV RNA was 5.18 (0.78)
log10 copies/ml at baseline, 4.45 (0.68) log10 copies/ml at week
48, and 4.40 (0.55) log10 copies/ml at week 96. The maximum
value of HIV RNA at either week 48 or 96 was 5.34 log10
copies/ml (219,000 copies/ml). Mean VRAs were similar at
week 48 (0.90 [SD, 0.78] log10 copies/ml) and week 96 (0.78
[SD, 0.80] log10 copies/ml). VRA was negative—that is, HIV
RNA at week 48/96 exceeded baseline value—for 27% (7/26)
of the observations. The association between VRA and zido-
vudine FC was weak and nonsignificant (Fig. 1a), with VRA
decreasing by an estimated 0.09 (95% confidence interval [95%
CI], 0.02 to 0.21) log10 copies/ml per 2-fold increase in zido-
vudine (P  0.12).
ZDV-3TC-ABC. A total of 56 observations on 49 patients
(i.e., 7 patients had observations at both 48 and 96 weeks) met
the inclusion criteria in the zidovudine-lamivudine-abacavir
(ZDV-3TC-ABC) group (Table 1). The only abacavir-associ-
ated mutation observed, other than M184V, was K65R in a
single patient at week 96. Sixty-six percent (19/29) of the sam-
ples had one or more TAMs at 48 weeks (median of 2), which
increased to 93% (25/27) of samples at 96 weeks (median of 3).
The median (IQR) FCs for abacavir were 0.7 (0.4, 1.0), 1.9
(1.5, 3.0), and 2.4 (1.4, 3.3) at weeks 0, 48, and 96, respectively;
the corresponding values for zidovudine FC were 0.9 (0.6, 1.3),
1.5 (1.1, 3.9), and 3.6 (1.6, 5.0).
Mean (SD) HIV RNA was 5.64 (0.58) log10 copies/ml at
baseline, 4.06 (0.69) log10 copies/ml at week 48, and 4.30 (0.75)
log10 copies/ml at week 96. The maximum value of HIV RNA
at either week 48 or week 96 was 5.33 log10 copies/ml (211,000
copies/ml). Mean VRA was 1.62 (0.72) log10 copies/ml at week
48 and 1.29 (0.70) log10 copies/ml at week 96. VRA was neg-
ative for only 2% (1/56) of the observations.
VRA was inversely related to both abacavir FC and zidovu-
dine FC (Fig. 1b and c). As expected, due to genotypic cross-
resistance, abacavir FC and zidovudine FC were strongly cor-
related (Fig. 2) (Pearson correlation coefficient, 0.55; 95% CI,
0.33 to 0.71). The best-fitting model indicated a linear effect of
zidovudine FC on VRA (decrease of 0.11 [95% CI, 0.02 to
0.21] per 2-fold increase, P 0.01), similar to that observed for
the ZDV-3TC-ABC group. However, a cubic transformation
of abacavir FC gave a statistically superior fit compared with a
linear model (P  0.02). Graphical representation of this as-
sociation indicates that the activity of abacavir changes little
for FC values less than approximately 2 but falls rapidly there-
after (Fig. 1b). Figure 1c shows the analogous plot for zidovu-
dine FC, at selected values of abacavir FC.
DISCUSSION
A striking finding in NORA was the observation of a max-
imum HIV RNA of 219,000 copies/ml among patients on an-
tiretroviral therapy compared with a pretherapy baseline me-
dian HIV RNA of 284,000 copies/ml (23). This suggested a
large VRA effect and motivated a detailed analysis of this
measure at the individual patient level. VRA was estimated by
comparing HIV RNA values after 48 and 96 weeks of therapy
with pretherapy values, analogous to the approach used in
some studies of monotherapy and dual therapy. Estimates of
FIG. 1. (a) Virological residual activity (VRA) related to zidovu-
dine fold change (FC) in ZDV-3TC-NVP group: individual data and
predicted values. Predicted values for baseline HIV RNA of 5.6 log10
copies/ml. (b) VRA related to abacavir FC in ZDV-3TC-ABC group:
individual data and predicted values. Predicted values for baseline
HIV RNA of 5.6 log10 copies/ml and ZDV FC of 1 (black line), ZDV
FC of 5 (dark-gray line), and ZDV FC of 20 (light-gray line). (c) VRA
related to zidovudine FC in ZDV-3TC-ABC group: individual data
and predicted values. Predicted values for baseline HIV RNA of 5.6
log10 copies/ml and ABC FC of 1 (black line), ABC FC of 2 (dark-gray
line), and ABC FC of 5 (light-gray line).
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VRA from these and other studies (6) for the antiretroviral
drugs used in NORA (zidovudine, lamivudine, nevirapine,
abacavir), either as single agents or in combination, are avail-
able in the supplemental material.
Because of uniformly high-level resistance to lamivudine
and nevirapine caused by single point mutations, we were un-
able to characterize the effects of these drugs. However, the
studies with results shown in Table S1 in the supplemental
material imply that there was likely to have been no or little
VRA from nevirapine whereas lamivudine may have resulted
in an approximate 0.5-log10 reduction (3-fold) in HIV RNA
plasma concentration. As VRA reflects the effect of the regi-
men as a whole, the estimates for zidovudine and abacavir
should be interpreted as being superimposed upon this effect.
Furthermore, there may be an additional indirect effect, since
the continued use of lamivudine maintains the M184V muta-
tion, which partially reverses zidovudine resistance (1).
The relationship between zidovudine FC and VRA was
weak in both the ZDV-3TC-ABC and the ZDV-3TC-NVP
group, with a doubling of ZDV FC predicting a reduction in
VRA of approximately 0.1 log10 copies/ml. This observation
was not unexpected, as zidovudine is a relatively nonpotent
drug, producing a maximum HIV RNA reduction of approxi-
mately 0.5 log10 copies/ml when given as monotherapy (2, 11,
13, 27), and has no discernible antiviral effect with a highly
mutated virus. The latter observation is at odds with in vitro
data showing that TAMs impair viral fitness (21), although this
may be countered partly by the development of compensatory
mutations (5).
In contrast with zidovudine, we observed that the level of
abacavir phenotypic resistance was an important determinant
of VRA, underscoring that VRA is not an absolute phenom-
enon but depends on the extent of resistance in a particular
viral isolate (9). Given the considerable experimental variabil-
ity in the estimation of FC, the association between VRA and
“true” abacavir FC may be even stronger than the empirical
association (14). An important finding is the apparent nonlin-
ear effect of abacavir FC, with the reduction in VRA being
incrementally greater the higher the value of abacavir FC. It is
noted that the maximum abacavir FC observed in our study
(5.2, excluding the sample with the 69 insertion complex) is
considerably lower than those described elsewhere for treat-
ment-experienced patients (19).
A key objective in clinical research has been the identifica-
tion of cut-points for phenotypic resistance assays that signify
when the effect of a drug ceases to exert meaningful clinical
activity (3, 29, 30). However, threshold effects often lack bio-
logical plausibility, and arbitrary statistical rules underlie se-
lection of cut-points. We also note that very large data sets are
required to reliably identify the precise form of relationships
where both the predictor (FC) and outcome (HIV RNA) vari-
ables are measured imprecisely, particularly when attempting
to separate the effects of individual components of a combi-
nation drug regimen. Lanier and colleagues used an add-in
design to examine the effect of abacavir on virological response
at 4 weeks (19). Using the statistical technique of recursive
partitioning, they identified Antivirogram FC cut-points of 3.2
and 7.5, although examination of the empirical data (Fig. 3B in
their paper) casts doubt on the reliability of these values; for
example, there were only 10 samples with abacavir FC values
above 7. Winters and colleagues sought to identify cut-points
by fitting linear regression models to a large, combined clinical
trial and cohort data set, on the basis of loss of drug activity
relative to that for wild-type virus, using HIV RNA response at
8 weeks (29, 30). They estimated 80% loss of abacavir activity
at an FC value of 3.5, although this was a predicted, rather than
a directly measured, FC value based on a genotypic algorithm.
Our analysis suggests an appreciable loss of abacavir antiviral
activity at FC values higher than approximately 2.
It should be emphasized that the association between VRA
and FC could be estimated only for subjects with HIV RNA
greater than 1,000 copies/ml (3.0 log10 copies/ml), the technical
limit for reliable resistance phenotyping. Thus, for a subject
whose baseline HIV RNA was 4.5 log10 copies/ml, the maxi-
mum observable VRA was 1.5 log10 copies/ml. This phenom-
enon, combined with variability in the measurement of HIV
RNA, explains in large part the strong relationship between
VRA and baseline HIV RNA. To explore potential bias, we
performed a simple simulation study in which we refitted mod-
els after imputing FC values for samples with HIV RNA less
than 1,000 copies/ml; these were assumed to harbor no signif-
icant resistance mutations and to have FC distributions that
mirrored those of pretherapy samples. This resulted in regres-
sion lines between VRA and observed FC value which were
shifted upwards and more steeply negative (not shown). How-
ever, from a clinical standpoint, our empirical analysis may be
the most relevant since subjects with low HIV RNA values are
not generally considered for treatment switches.
The usefulness of VRA in resource-rich settings is most
apparent in helping to guide the selection of salvage regimens
in patients with a highly resistant virus. However, its clinical
relevance is arguably more pertinent in resource-limited set-
tings, where rapid switching after detection of virological fail-
ure may not be feasible because of the lack of concurrent viral
load monitoring and limited access to second-line and subse-
quent regimens (15). The PLATO study of patients with three-
class virological failure found that CD4 count tended to in-
crease if current HIV RNA was less than 4.0 log10 copies/ml or
if VRA exceeded 1.5 log10 copies/ml (20). In the ZDV-3TC-
NVP group, average VRA was only 0.8 log10 copies/ml (largely
FIG. 2. Correlation between abacavir fold change (FC) and zidovu-
dine FC. Circles, week 48; squares, week 96.
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independent of the level of resistance to zidovudine), and HIV
RNA was actually higher at week 48/96 than at baseline for
27% of paired samples. This suggests that there is likely to be
no or limited clinical benefit in continuing this regimen follow-
ing virological failure. In contrast, ZDV-3TC-ABC demon-
strated more-potent virological activity in the presence of re-
sistance, with mean VRAs of 1.7 and 1.2 log10 copies/ml at
weeks 48 and 96, respectively.
The key determinant of VRA, from our analysis, appears to
be the level of resistance to abacavir. Many viral isolates re-
mained susceptible to this drug, although this proportion is
anticipated to decrease as further mutations accumulate as a
result of prolonged virological failure. As discussed earlier, the
identification of individual virological failure or of resistance
patterns is rarely possible in resource-limited settings. Infor-
mation on the population distribution of HIV RNA, particu-
larly the proportion of patients remaining virologically sup-
pressed by time on therapy, is critical to guide programmatic
decisions. Such analyses of the regimens used in the DART
trial are ongoing.
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